I found the first page of this article provided a good and fairly understandable overview of where we are with chimeric antigen receptors (CARs) and in particular with the use of the T-cell receptor CAR-T). Much of the article is devoted to blood cancers, in particular B-cell cancers, with CLL specifically mentioned. "Since CD19 is found on the cell surface in most leukemias and lymphomas, but nowhere else in the body except for B-lineage cells, it is an attractive target for therapy. In addition, CD19 has been implicated in tumor survival, making it more likely to be present on—and less likely to be lost from—all tumor cells."
There's also some very encouraging news on progress towards overcoming the major disadvantage so far with CAR-T - the personalised and therefore expensive approach. "We are developing off-the-shelf T cells before the patient arrives at a treatment facility,” asserts Dr. Cooper. “This enables a biobank of T cells to be pre-prepared, which could be a one-time cost.”